Loading patent…
AssigneePharmacia Corporation
InventorJames W. Aiken
Estimating the term…
A method for treating or preventing ophthalmic disorders comprising the administration of one or more aldosterone receptor antagonists that contain a 9,11-epoxy moiety, such as eplerenone is disclosed. The method results in a reduction of intraocular pressure which treats or prevents the ophthalmic disorders. Among the disorders are intraocular hypertension, glaucoma, low tension glaucoma, age-related macular degeneration (AMD), macular edema, and diabetic retinopathy. As glucocorticoids and mineralocorticoids also cause the retention of ions, such as sodium and potassium, where aldosterone receptors are located, aldosterone receptor antagonists that contain a 9,11-epoxy moiety, such as eplerenone, also can be administered to modulate the intraocular concentration of ions. Thus, aldosterone receptor antagonists can be administered to maintain an intraocular ionic environment that is beneficial to intraocular cell survival.
A method of reducing intraocular pressure in a subject having elevated intraocular pressure or having a condition which places them at risk for elevated intraocular pressure, comprising administering a therapeutically effective amount of an epoxy-steroidal aldosterone receptor antagonist to the subject.
The method of 5 wherein the second ingredient is a compound that accelerates the outflow of aqueous humor from the anterior chamber selected from the group consisting of a cytoskeletal disrupting agent, prostaglandin compound, or combinations thereof.
The method of 6 wherein the prostaglandin compound is selected from the group consisting of PGA, PGB, PGD, PGE, PGF, their derivatives, latanoprost, a combination of latanoprost and timilol, unoprostone isopropyl ophthalmic solution, lumigan, travaprost, unoprostone, PGF2α agonists, prostanoids, prostaglandin pro-drugs, and combinations thereof.
A method of treating an ocular disease of a subject comprising administering a therapeutically effective amount of an epoxy-steroidal aldosterone receptor antagonist to the subject wherein the ocular disease is selected from the group consisting of intraocular hypertension, glaucoma, low tension glaucoma, age-related macular degeneration (AMD), macular edema, and diabetic retinopathy.
A method of modulating intraocular levels of ions comprising administering epoxy-steroidal aldosterone receptor antagonists that contains a 9,11-epoxy moiety.
The method of 26 wherein the ions are selected from the group consisting of sodium and potassium.
The method of 26 wherein the 9,11-epoxy-steroidal aldosterone receptor antagonist is eplerenone.
A method of treating or preventing an ophthalmic disorder comprising coadministering an epoxy-steroidal aldosterone receptor antagonist and a second compound that accelerates the outflow of aqueous humor from the anterior chamber, such as a cytoskeletal disrupting agent, prostaglandin compound, or combination thereof.
A method of treating or preventing an ophthalmic disorder comprising coadministering an epoxy-steroidal aldosterone receptor antagonist and a second compound that reduces inflow of aqueous humor into the anterior chamber, such as a cholinergic agent, sympathomimetic, carbonic anhydrase inhibitor, or combination thereof.
A composition for treating or preventing an ophthalmic disorder comprising an epoxy-steroidal aldosterone receptor antagonist and second compound that accelerates the outflow of aqueous humor from the anterior chamber, such as a cytoskeletal disrupting agent, prostaglandin compound, or combination thereof.
A composition for treating or preventing an ophthalmic disorder comprising an epoxy-steroidal aldosterone receptor antagonist and second compound that reduces inflow of aqueous humor into the anterior chamber, such as a cholinergic agent, sympathomimetic, carbonic anhydrase inhibitor, or combination thereof.
A kit for treating or preventing an ophthalmic disorder comprising an epoxy-steroidal aldosterone receptor antagonist and a second compound that accelerates the outflow of aqueous humor from the anterior chamber, such as a cytoskeletal disrupting agent, prostaglandin compound, or combination thereof.
A kit for treating or preventing an ophthalmic disorder comprising an epoxy-steroidal aldosterone receptor antagonist and a second compound that reduces inflow of aqueous humor into the anterior chamber, such as a cholinergic agent, sympathomimetic, carbonic anhydrase inhibitor, or combination thereof.
Dependencies are inferred from the claim text.